Impact of Disease and Treatment Response in Drug-Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non‐Small Cell Lung Cancer by Karthick Vishwanathan, Mireille Cantarini, Karen So, Eric Masson, Jennifer Fetterolf, Suresh S. Ramalingam, R. Donald Harvey

Connect to this object online.

Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach by Diansong Zhou, Terry Podoll, Yan Xu, Ganesh Moorthy, Karthick Vishwanathan, Joseph Ware, J. Greg Slatter, Nidal Al‐Huniti

Connect to this object online.

A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment by Karthick Vishwanathan, Inmaculada Sanchez‐Simon, Bhumsuk Keam, Nicolas Penel, Maria deMiguel‐Luken, Doris Weilert, Andrew Mills, Marcelo Marotti, Martin Johnson, Alain Ravaud

Connect to this object online.

A mechanistic PK/PD model of AZD0171 (anti‐LIF) to support Phase II dose selection by Azar Shahraz, Mark Penney, Juliana Candido, Grace Opoku‐Ansah, Melanie Neubauer, Jim Eyles, Oluwaseun Ojo, Nelson Liu, Nadia M. Luheshi, Alex Phipps, Karthick Vishwanathan

Connect to this object online.

Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non‐small cell lung cancer and brain metastases: A positron emission tomography and magneti... by Simon Ekman, Zsolt Cselényi, Andrea Varrone, Aurelija Jucaite, Heather Martin, Magnus Schou, Peter Johnström, Gianluca Laus, Rolf Lewensohn, Andrew P. Brown, Jasper van derAart, Karthick Vishwanathan, Lars Farde

Connect to this object online.